- Home
- PLCI vs NYXH Comparison
PLCI vs NYXH Comparison
Compare PLCI & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLCI | NYXH |
|---|---|---|
| Founded | 2026 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.2M | 137.5M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLCI | NYXH |
|---|---|---|
| Price | $9.89 | $0.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.78 |
| AVG Volume (30 Days) | 12.1K | ★ 223.2K |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $247.05 |
| Revenue Next Year | N/A | $99.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.84 | $0.80 |
| 52 Week High | $10.44 | $5.92 |
Technical Indicators
Market Signals| Indicator | PLCI | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 30.11 |
| Support Level | $9.88 | $0.80 |
| Resistance Level | $9.92 | $1.69 |
| Average True Range (ATR) | 0.01 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 25.00 | 18.06 |
Price Performance
Historical ComparisonAbout PLCI Pelican Acquisition II Corporation Ordinary Shares
Pelican Acquisition II Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.